Drugs / EB-MF-CAR-NK-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07510815 | Mar 2026 → Mar 2027 expected | malignant pleural mesothelioma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-MF-CAR-NK-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07510815 ↗ |
| Modality | Cell therapy | “dual-target allogeneic CAR-NK product” NCT07510815 ↗ |
| Route | Other | “Delivery is intrapleural for pleural mesothelioma and intraperitoneal for peritoneal mesothelioma.” NCT07510815 ↗ |